Evotec has entered an agreement to acquire Cyprotex for a consideration of $67.5m.
According to the agreement, Evotec will acquire all the outstanding shares of Cyprotex at a price of $1.95 a share.
Go deeper with GlobalData
MCF Limited and N+1 Singer Advisory are acting as financial advisors for the transaction for Evotec and Cyprotex respectively.
The acquisition will enable Evotec to expand its drug discovery platform.
Shandong Jincheng Pharmaceutical plans to become the 100% stake holder in Beijing Jincheng Haichuang Biological Technology by acquiring the remaining 15% stake in the company.
The acquirer company has agreed to purchase the remaining stakes from Wang Haisheng for a consideration of $0.014m.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe transaction is expected to be completed by 25 November.
I’rom Group, a site management organisation and medical support services provider, plans to acquire a 61% stake in clinical trial services provider CMAX.
The company expects the transaction to cost up to $7.61m.
Pursuant to the transaction, the company plans to become a 100% stake holder in June 2017 by acquiring the remaining shares in CMAX.
